S&P 500   3,916.64
DOW   31,861.98
QQQ   305.30
Risk-Free Money Market vs. Bank Dividend Stock, Which is Better?
Fed's Shocking New Plan to Control Your Money (Ad)
Deal for UBS to buy Credit Suisse sends shares tumbling
Gunmen kill 9 Chinese at mine in Central African Republic
Buy THIS stock before Taiwan is attacked (Ad)
Niinistö: Sweden security OK if Finland joins NATO first
The End of Coca Cola's Compressed Margins
Buy THIS stock before Taiwan is attacked (Ad)
Which Gold Stocks Can Help You Hedge Bank Exposure?
Enphase Energy is Still a Buy for Long-Term Growth Investors
S&P 500   3,916.64
DOW   31,861.98
QQQ   305.30
Risk-Free Money Market vs. Bank Dividend Stock, Which is Better?
Fed's Shocking New Plan to Control Your Money (Ad)
Deal for UBS to buy Credit Suisse sends shares tumbling
Gunmen kill 9 Chinese at mine in Central African Republic
Buy THIS stock before Taiwan is attacked (Ad)
Niinistö: Sweden security OK if Finland joins NATO first
The End of Coca Cola's Compressed Margins
Buy THIS stock before Taiwan is attacked (Ad)
Which Gold Stocks Can Help You Hedge Bank Exposure?
Enphase Energy is Still a Buy for Long-Term Growth Investors
S&P 500   3,916.64
DOW   31,861.98
QQQ   305.30
Risk-Free Money Market vs. Bank Dividend Stock, Which is Better?
Fed's Shocking New Plan to Control Your Money (Ad)
Deal for UBS to buy Credit Suisse sends shares tumbling
Gunmen kill 9 Chinese at mine in Central African Republic
Buy THIS stock before Taiwan is attacked (Ad)
Niinistö: Sweden security OK if Finland joins NATO first
The End of Coca Cola's Compressed Margins
Buy THIS stock before Taiwan is attacked (Ad)
Which Gold Stocks Can Help You Hedge Bank Exposure?
Enphase Energy is Still a Buy for Long-Term Growth Investors
S&P 500   3,916.64
DOW   31,861.98
QQQ   305.30
Risk-Free Money Market vs. Bank Dividend Stock, Which is Better?
Fed's Shocking New Plan to Control Your Money (Ad)
Deal for UBS to buy Credit Suisse sends shares tumbling
Gunmen kill 9 Chinese at mine in Central African Republic
Buy THIS stock before Taiwan is attacked (Ad)
Niinistö: Sweden security OK if Finland joins NATO first
The End of Coca Cola's Compressed Margins
Buy THIS stock before Taiwan is attacked (Ad)
Which Gold Stocks Can Help You Hedge Bank Exposure?
Enphase Energy is Still a Buy for Long-Term Growth Investors
NASDAQ:ADAG

Adagene - ADAG Stock Forecast, Price & News

$1.59
-0.01 (-0.71%)
(As of 03/17/2023 06:55 PM ET)
Add
Compare
Today's Range
$1.43
▼
$1.61
50-Day Range
$1.35
▼
$1.95
52-Week Range
$0.90
▼
$4.84
Volume
12,600 shs
Average Volume
27,365 shs
Market Capitalization
$68.71 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00

Adagene MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
214.7% Upside
$5.00 Price Target
Short Interest
Healthy
0.02% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.55mentions of Adagene in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.72) to ($2.07) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.33 out of 5 stars

Medical Sector

250th out of 983 stocks

Pharmaceutical Preparations Industry

107th out of 480 stocks

See Top Rated MarketRank™ Stocks Here

ADAG stock logo

About Adagene (NASDAQ:ADAG) Stock

Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of advanced metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody, which is in preclinical; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical stage for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody, which is in preclinical stage for the treatment off-tumor toxicities. The company was incorporated in 2011 and is headquartered in Suzhou, China.

Receive ADAG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adagene and its competitors with MarketBeat's FREE daily newsletter.

ADAG Stock News Headlines

March 16, 2023 | markets.businessinsider.com
H.C. Wainwright Keeps Their Buy Rating on Hookipa Pharma (HOOK)
March 16, 2023 | americanbankingnews.com
Adagene Inc. (NASDAQ:ADAG) Short Interest Down 10.9% in February
March 20, 2023 | Legacy Research (Affiliate) (Ad)
"Prepare for Five Years of Famine"
Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecast
March 14, 2023 | finance.yahoo.com
Adagene Announces Poster Presentations on Anti-CTLA-4 SAFEbody®, ADG126, at Upcoming American Association for Cancer Research (AACR) Annual Meeting in April
January 9, 2023 | finance.yahoo.com
Adagene Announces Interim Data Demonstrating Safety and Confirmed Clinical Responses of Anti-CTLA-4 SAFEbody® ADG126 up to 10 mg/kg with Repeat Cycles in Combination with Anti-PD-1 Therapy from Dose Escalation Portion of Phase 1b/2 Trial
January 5, 2023 | finance.yahoo.com
Adagene to Present at the Biotech Showcase™ 2023 in San Francisco on January 9
December 22, 2022 | markets.businessinsider.com
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Teladoc (TDOC) and Adagene (ADAG)
December 19, 2022 | benzinga.com
After One-Off Cash Infusions, YZY Biopharma Looks for More Funds From IPO
March 20, 2023 | Legacy Research (Affiliate) (Ad)
"Prepare for Five Years of Famine"
Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecast
December 16, 2022 | seekingalpha.com
Adagene adds 12% on clinical trial collaboration with Roche
December 16, 2022 | finance.yahoo.com
Adagene Announces Clinical Trial Collaboration to Evaluate Anti-CTLA-4 SAFEbody® ADG126 in Combination with Roche’s Standard-of-Care for First-Line Advanced Liver Cancer
November 21, 2022 | finance.yahoo.com
Adagene Appoints Cuong Do to Board of Directors and Audit Committee
November 14, 2022 | finance.yahoo.com
DelveInsight Highlights Major Advances, Transformative Therapies and 180+ Leading Players Wheeling the PD-1 and PD-L1 Inhibitors Pipeline Landscape
November 10, 2022 | finance.yahoo.com
Adagene Announces Clinical Data at SITC 2022 on Anti-CTLA-4 NEObody™, ADG116, Showing Differentiated Safety and Anti-tumor Activity in Heavily Pre-treated Patients with Difficult-to-Treat Tumors
October 11, 2022 | finance.yahoo.com
Adagene Announces Poster Presentations on Anti-CTLA-4 NEObody™, ADG116, at Upcoming Society for Immunotherapy of Cancer’s (SITC) Annual Meeting in November
September 10, 2022 | finance.yahoo.com
Adagene Presents Interim Monotherapy Data at ESMO 2022 Showing Compelling Safety, Anti-Tumor Activity and Pharmacokinetics of Masked, Anti-CTLA-4 SAFEbody® ADG126 in Patients with Advanced Tumors
September 1, 2022 | nz.finance.yahoo.com
Healee Lands $2M to Grow Customizable Telehealth Solution in the U.S.
August 30, 2022 | wsj.com
JW (Cayman) Therapeutics Co. Ltd.
August 30, 2022 | finance.yahoo.com
Adagene Reports Financial Results for the Six Months Ended June 30, 2022 and Provides Corporate Updates
August 26, 2022 | benzinga.com
Global CD47 Inhibitor Drug Clinical Trial Report...
August 25, 2022 | finance.yahoo.com
Adagene Inc. (ADAG)
July 1, 2022 | seekingalpha.com
Micro-cap Adagene surges after hours on $10M share buyback
June 29, 2022 | marketwatch.com
Adagene ADSs Rise 16% After Co. Announces Repurchase Plan
June 29, 2022 | finance.yahoo.com
Adagene Announces Authorization of Share Repurchase Program up to US$10 Million
June 26, 2022 | nasdaq.com
China’s Economy, Geopolitical Risk and Zero Covid Policies
June 23, 2022 | seekingalpha.com
China's Economy, Geopolitical Risk, And Zero Covid Policies
May 26, 2022 | finance.yahoo.com
Adagene Announces Publication at ASCO of Interim Monotherapy Dose Escalation Data Showing Compelling Safety Profile of Anti-CTLA-4 SAFEbody® ADG126, with Repeat Dosing Across Dose Levels
See More Headlines
Receive ADAG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adagene and its competitors with MarketBeat's FREE daily newsletter.

ADAG Company Calendar

Today
3/19/2023
Next Earnings (Estimated)
3/30/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ADAG
CUSIP
N/A
CIK
1818838
Web
www.adagene.com
Phone
86-512-8777-3632
Fax
N/A
Employees
198
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$5.00
High Stock Price Forecast
$5.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+214.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
0.08
Current Ratio
3.10
Quick Ratio
N/A

Sales & Book Value

Annual Sales
$10.18 million
Price / Sales
6.75
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.58 per share
Price / Book
0.44

Miscellaneous

Outstanding Shares
43,250,000
Free Float
34,083,000
Market Cap
$68.71 million
Optionable
Not Optionable
Beta
0.07

Key Executives

  • Dr. Peter P. Luo Ph.D. (Age 56)
    Co-Founder, CEO & Chairman
  • Mr. Man Kin Tam M.B.A. (Age 45)
    CFO & Director
  • Dr. Fangyong Du Ph.D. (Age 52)
    Chief Technology Officer
  • Dr. Jc Xu M.D. (Age 57)
    Ph.D., Chief Scientific Officer
  • Ms. Ami Celeste Knoefler
    VP of Investor Relations & Corp. Communications
  • Ms. Ling Zhou
    Head of HR
  • Dr. Qinghai Zhao (Age 61)
    Chief Manufacturing Officer
  • Ms. Yan Li M.B.A. (Age 47)
    Sr. VP of Bioinformatics & Information Technology
  • Ms. Xiaohong She (Age 55)
    Sr. VP & Head of Clinical Operations
  • Dr. Guizhong Liu Ph.D. (Age 51)
    Head of Biology & Pharmacology

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions













ADAG Stock - Frequently Asked Questions

Should I buy or sell Adagene stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Adagene in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ADAG shares.
View ADAG analyst ratings or view top-rated stocks.

What is Adagene's stock price forecast for 2023?

2 brokers have issued 1 year price objectives for Adagene's stock. Their ADAG share price forecasts range from $5.00 to $5.00. On average, they expect the company's share price to reach $5.00 in the next twelve months. This suggests a possible upside of 214.7% from the stock's current price.
View analysts price targets for ADAG or view top-rated stocks among Wall Street analysts.

How have ADAG shares performed in 2023?

Adagene's stock was trading at $1.3250 at the start of the year. Since then, ADAG stock has increased by 19.9% and is now trading at $1.5887.
View the best growth stocks for 2023 here.

Are investors shorting Adagene?

Adagene saw a decline in short interest during the month of February. As of February 28th, there was short interest totaling 8,200 shares, a decline of 10.9% from the February 13th total of 9,200 shares. Based on an average trading volume of 42,500 shares, the days-to-cover ratio is presently 0.2 days. Approximately 0.0% of the shares of the stock are short sold.
View Adagene's Short Interest.

When is Adagene's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 30th 2023.
View our ADAG earnings forecast.

When did Adagene IPO?

(ADAG) raised $133 million in an IPO on Tuesday, February 9th 2021. The company issued 7,400,000 shares at a price of $17.00-$19.00 per share. Goldman Sachs (Asia), Morgan Stanley and Jefferies acted as the underwriters for the IPO and China Renaissance was co-manager.

What is Adagene's stock symbol?

Adagene trades on the NASDAQ under the ticker symbol "ADAG."

Who are Adagene's major shareholders?

Adagene's stock is owned by many different retail and institutional investors. Top institutional investors include Strategic Vision Investment Ltd (0.84%) and Renaissance Technologies LLC (0.17%).

How do I buy shares of Adagene?

Shares of ADAG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Adagene's stock price today?

One share of ADAG stock can currently be purchased for approximately $1.59.

How much money does Adagene make?

Adagene (NASDAQ:ADAG) has a market capitalization of $68.71 million and generates $10.18 million in revenue each year.

How many employees does Adagene have?

The company employs 198 workers across the globe.

How can I contact Adagene?

Adagene's mailing address is 4F BUILDING C14 NO. 218 XINGHU STREET SUZHOU INDUSTRIAL PARK, JIANGSU F4, 215123. The official website for the company is www.adagene.com. The company can be reached via phone at 86-512-8777-3632 or via email at ir@adagene.com.

This page (NASDAQ:ADAG) was last updated on 3/20/2023 by MarketBeat.com Staff